WO2000027425A3 - Pharmaceutical preparation containing a receptor-antagonist for treating blood-clotting disorders - Google Patents

Pharmaceutical preparation containing a receptor-antagonist for treating blood-clotting disorders Download PDF

Info

Publication number
WO2000027425A3
WO2000027425A3 PCT/AT1999/000271 AT9900271W WO0027425A3 WO 2000027425 A3 WO2000027425 A3 WO 2000027425A3 AT 9900271 W AT9900271 W AT 9900271W WO 0027425 A3 WO0027425 A3 WO 0027425A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical preparation
receptor
antagonist
treating blood
preparation containing
Prior art date
Application number
PCT/AT1999/000271
Other languages
German (de)
French (fr)
Other versions
WO2000027425A2 (en
Inventor
Hans-Peter Schwarz
Peter Turecek
Bernd Binder
Original Assignee
Baxter Ag
Schwarz Hans Peter
Peter Turecek
Bernd Binder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Ag, Schwarz Hans Peter, Peter Turecek, Bernd Binder filed Critical Baxter Ag
Priority to DE59909356T priority Critical patent/DE59909356D1/en
Priority to CA002349644A priority patent/CA2349644A1/en
Priority to DK99955585T priority patent/DK1128841T3/en
Priority to AU12527/00A priority patent/AU1252700A/en
Priority to AT99955585T priority patent/ATE265225T1/en
Priority to JP2000580654A priority patent/JP2002529424A/en
Priority to EP99955585A priority patent/EP1128841B1/en
Publication of WO2000027425A2 publication Critical patent/WO2000027425A2/en
Publication of WO2000027425A3 publication Critical patent/WO2000027425A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases

Abstract

The invention relates to a pharmaceutical preparation for treating blood-clotting disorders which is characterized in that it contains at least one protein selected from the group of pro-proteins of the blood clotting and additionally contains a coagulation-physiologically inert receptor binding competitor. The invention also relates to the medical application of said preparation.
PCT/AT1999/000271 1998-11-10 1999-11-10 Pharmaceutical preparation containing a receptor-antagonist for treating blood-clotting disorders WO2000027425A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE59909356T DE59909356D1 (en) 1998-11-10 1999-11-10 PHARMACEUTICAL PREPARATION CONTAINING A RECEPTOR ANTAGONIST FOR THE TREATMENT OF BLOOD COagulation disorders
CA002349644A CA2349644A1 (en) 1998-11-10 1999-11-10 Pharmaceutical preparation containing a receptor-antagonist for treating blood-clotting disorders
DK99955585T DK1128841T3 (en) 1998-11-10 1999-11-10 Pharmaceutical composition containing a receptor antagonist for the treatment of blood clotting disorders
AU12527/00A AU1252700A (en) 1998-11-10 1999-11-10 Pharmaceutical preparation containing a receptor-antagonist for treating blood-clotting disorders
AT99955585T ATE265225T1 (en) 1998-11-10 1999-11-10 PHARMACEUTICAL PREPARATION CONTAINING A RECEPTOR ANTAGONIST FOR THE TREATMENT OF BLOOD CLOTTING DISORDERS
JP2000580654A JP2002529424A (en) 1998-11-10 1999-11-10 Pharmaceutical preparations containing receptor antagonists for treating blood coagulation disorders
EP99955585A EP1128841B1 (en) 1998-11-10 1999-11-10 Pharmaceutical preparation containing a receptor-antagonist for treating blood-clotting disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA1873/98 1998-11-10
AT0187398A AT409335B (en) 1998-11-10 1998-11-10 PHARMACEUTICAL PREPARATION CONTAINING A RECEPTOR ANTAGONIST FOR THE TREATMENT OF BLOOD COagulation disorders

Publications (2)

Publication Number Publication Date
WO2000027425A2 WO2000027425A2 (en) 2000-05-18
WO2000027425A3 true WO2000027425A3 (en) 2000-08-31

Family

ID=3522864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT1999/000271 WO2000027425A2 (en) 1998-11-10 1999-11-10 Pharmaceutical preparation containing a receptor-antagonist for treating blood-clotting disorders

Country Status (10)

Country Link
EP (1) EP1128841B1 (en)
JP (1) JP2002529424A (en)
AT (2) AT409335B (en)
AU (1) AU1252700A (en)
CA (1) CA2349644A1 (en)
DE (1) DE59909356D1 (en)
DK (1) DK1128841T3 (en)
ES (1) ES2221457T3 (en)
PT (1) PT1128841E (en)
WO (1) WO2000027425A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5282200A (en) * 1999-05-24 2000-12-12 American National Red Cross, The Methods of reducing factor viii clearance and compositions therefor
US7615622B2 (en) 2001-01-12 2009-11-10 University Of Maryland, Baltimore Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
JP2005510514A (en) * 2001-11-09 2005-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Pharmaceutical compositions comprising a Factor VII polypeptide and a PAI-1 polypeptide
DK1497330T3 (en) * 2002-04-29 2010-06-14 Sanquin Bloedvoorziening Antagonists of factor VIII interaction with low-density lipoprotein receptor-related protein
US20060233786A1 (en) * 2002-05-23 2006-10-19 Chugai Seiyaku Kabushiki Kaisha Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation
EP1454632A1 (en) * 2003-02-07 2004-09-08 Aventis Behring GmbH, Intellectual Property/Legal Pharmaceutical preparation for the treatment of blood-clotting disorders containing factor VIII derived peptides
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0519900A1 (en) * 1991-06-20 1992-12-23 IMMUNO Aktiengesellschaft Pharmaceutical preparation containing a thrombolytically active substance and Protein C
WO1994014471A1 (en) * 1992-12-18 1994-07-07 Washington University Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
WO1995025536A1 (en) * 1994-03-21 1995-09-28 Washington University Methods and compositions for inhibition of hepatic clearance of tissue factor pathway inhibitor
WO1997034930A1 (en) * 1996-03-15 1997-09-25 Immuno Aktiengesellschaft Stable factor viii/ von willebrand factor complex
WO1998032459A1 (en) * 1997-01-29 1998-07-30 University Technology Corporation Plasminogen activator as an anti-inflammatory agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4115453A1 (en) * 1991-05-11 1992-11-12 Knoll Ag NEW ACTIVE COMPOUND
DE4437544A1 (en) * 1994-10-20 1996-04-25 Behringwerke Ag Use of vWF-containing concentrates as combination therapy for therapy with antithrombotics and fibrinolytics
DK0796623T3 (en) * 1996-03-20 2005-08-01 Baxter Ag Pharmaceutical composition for the treatment of blood clotting disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0519900A1 (en) * 1991-06-20 1992-12-23 IMMUNO Aktiengesellschaft Pharmaceutical preparation containing a thrombolytically active substance and Protein C
WO1994014471A1 (en) * 1992-12-18 1994-07-07 Washington University Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
WO1995025536A1 (en) * 1994-03-21 1995-09-28 Washington University Methods and compositions for inhibition of hepatic clearance of tissue factor pathway inhibitor
WO1997034930A1 (en) * 1996-03-15 1997-09-25 Immuno Aktiengesellschaft Stable factor viii/ von willebrand factor complex
WO1998032459A1 (en) * 1997-01-29 1998-07-30 University Technology Corporation Plasminogen activator as an anti-inflammatory agent

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KOUNNAS MARIA Z ET AL: "Cellular internalization and degradation of antithrombin III-thrombin, heparin cofactor II-thrombin, and alpha-1-antitrypsin-trypsin complexes is mediated by the low density lipoprotein receptor-related protein.", JOURNAL OF BIOLOGICAL CHEMISTRY 1996, vol. 271, no. 11, 1996, pages 6523 - 6529, XP002137879, ISSN: 0021-9258 *
NARITA MASAAKI ET AL: "The low-density lipoprotein receptor-related protein (LRP) mediates clearance of coagulation factor Xa in vivo.", BLOOD JAN. 15, 1998, vol. 91, no. 2, 15 January 1998 (1998-01-15), pages 555 - 560, XP002137878, ISSN: 0006-4971 *
NEELS ET AL: "ligand receptor interaction of the low density lipoprotein receptor-related protein, a multi-ligand endocytic receptor", FIBRINOLYSIS & PROTEOLYSIS, vol. 12, no. 4, 1998, pages 219 - 240, XP000907114 *
NOORMAN F ET AL: "regulation of tissue-type plasminogen activator concentration by clearance via the mannose receptor and other receptors", FIBRINOLYSIS & PROTEOLYSIS, vol. 11, no. 4, 1997, pages 173 - 186, XP000907181 *
SCHWARZ, HANS PETER ET AL: "Involvement of low-density lipoprotein receptor - related protein ( LRP ) in the clearance of factor VIII in von Willebrand factor -deficient mice", BLOOD (2000), 95(5), 1703-1708, XP002137880 *
YAKYAEV ET ALL: "cellular uptake and degradation of the thrombin activated factor VIII fragmets", BLOOD, vol. 90, no. 10, suppl 1, - 1997, pages 31a, XP000907187 *

Also Published As

Publication number Publication date
WO2000027425A2 (en) 2000-05-18
DK1128841T3 (en) 2004-08-16
ATA187398A (en) 2001-12-15
ES2221457T3 (en) 2004-12-16
DE59909356D1 (en) 2004-06-03
EP1128841A2 (en) 2001-09-05
AU1252700A (en) 2000-05-29
ATE265225T1 (en) 2004-05-15
AT409335B (en) 2002-07-25
EP1128841B1 (en) 2004-04-28
JP2002529424A (en) 2002-09-10
CA2349644A1 (en) 2000-05-18
PT1128841E (en) 2004-09-30

Similar Documents

Publication Publication Date Title
HUP9700603A3 (en) Pharmaceutical preparation for the treatment of blood coagulation disorders
WO2003057134A3 (en) Specific binding agents of human angiopoietin-2
BG109311A (en) PHARMACEUTICAL COMPOSITION INCLUDING HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha AND THE APPLICATION THEREOF
WO2002032374A3 (en) Methods for treating il-18 mediated disorders
NO963568D0 (en) Pharmaceutical composition for the treatment of blood coagulation disorders, methods for the preparation thereof and its use
IL159422A0 (en) Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
BR9710362A (en) Pharmaceutical formulation compound uses a compound processes of treatment of a human or animal suffering from a mediated by abnormal activity of protein tyrosine kinase and for the preparation of a compound
WO2000006085A3 (en) Compounds and methods
WO2001011048A3 (en) Therapeutic polypeptides and methods for using same
AU2742892A (en) An anticoagulant substance obtained from urine
WO2002093173A3 (en) Screening method using pim1-kinase or pim3-kinase
EP0651655A4 (en) Blockade of protein c activation reduces microvascular surgical blood loss.
WO2000027425A3 (en) Pharmaceutical preparation containing a receptor-antagonist for treating blood-clotting disorders
EP2241329A3 (en) Anti-interleukin-9 antibody or anti-interleukin-9 receptor antibody for treating bronchial hyper-responsiveness
EP0744176A3 (en) Methods for inhibiting bone loss
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
EP0373771A3 (en) New pharmaceutical uses for cystatins
WO2000015797A3 (en) Compositions and methods for the treatment of immune related diseases
WO2002058323A3 (en) Method for identifying modulators of bace
WO2002101394A3 (en) Screening method which uses bnpi and dnpi
WO1999050671A3 (en) Toso as a target for drug screening
WO2002070563A3 (en) Nuclear hormone receptor ligand binding domain
ZA983753B (en) Medicinal composition for treatment of burns, cuts and like wounds.
AU9245398A (en) Preparation for the therapy of disorders related to blood clotting
WO2001016319A3 (en) Compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2000 12527

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999955585

Country of ref document: EP

ENP Entry into the national phase

Kind code of ref document: A

Ref document number: 2349644

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2000 580654

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12527/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999955585

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09831680

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1999955585

Country of ref document: EP